Cath Lab Digest
VerifiedMagazine
Cath Lab Digest is a monthly news and clinical update for the cardiac catheterization laboratory specialist, focusing on coronary, peripheral vascular (including chronic limb-threatening ischemia), and structural heart disease interventional treatment and care. Source
Actions
Media Outlet details
| Scope | National, Trade/B2B |
|---|---|
| Language | English |
| Country | United States of America |
Similarweb UVM
|
Request pricing |
Comscore UVM
|
Request pricing |
| Frequency | Monthly |
Recent Articles
Search ArticlesClient Challenge
JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.
Six Medical Societies Call for Immediate Adoption of Enhanced Radiation Protection in Fluoroscopy Labs New multisociety expert consensus statement says safer technologies are available now and should become the standard for protecting healthcare workers.
Expert Consensus WASHINGTON—Healthcare professionals performing minimally invasive procedures in fluoroscopy laboratories, often called “cath labs,” should no longer have to accept preventable radiation exposure and orthopedic injuries as part of their jobs, according to an expert consensus statement released July 14th that is endorsed by six leading medical societies.
Elucid Announces First Patient Enrollment in AI-PREDICT, a Landmark International Study to Define Lesion-Level Cardiovascular Risk Multicenter Retrospective Study Will Analyze Lesions Using AI-Powered CCTA Analysis, Advancing Elucid’s CCTA 3.0 Vision for
BOSTON--Elucid, an innovator in AI-powered coronary CT angiography (CCTA) analysis, announced first patient enrollment in AI-PREDICT, a retrospective, international, multicenter study designed to establish a new lesion-centric paradigm for cardiovascular risk stratification.
Client Challenge
JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.
3-Year DETOUR2 Results Demonstrate Sustained Symptom Relief and Limb Preservation in Complex SFA Disease Data from one of the first studies in long-segment (>30 cm) FP disease show durable patency, low reintervention rate, and high limb salvage through 36
Santa Rosa, Calif. – Endologix LLC, a privately held, global medical device company focused on advancing innovative therapies for the interventional treatment of vascular disease, announced publication of 36-month results from the DETOUR2 clinical trial evaluating Percutaneous Transmural Arterial Bypass (PTAB) using the DETOUR™ System in the Journal of the Society for Cardiovascular Angiography and Interventions (JSCAI).
First Patient Enrolled in Penumbra’s FORWARD Study Evaluating Mechanical Thrombectomy and Computer Assisted Vacuum Thrombectomy for Distal Acute Ischemic Stroke
ALAMEDA, Calif. - Penumbra, Inc. announced the initiation of its FORWARD study, an international, real world prospective, multi-center study. The study will collect safety and efficacy data on mechanical thrombectomy, including computer assisted vacuum thrombectomy (CAVT™) and modulated aspiration, in the management of acute ischemic stroke with distal occlusions. The first patient was treated by Keith Woodward, M.D., neurointerventional radiologist at Vista Radiology in Knoxville, Tenn.
Ascension Adds 300 ASCs With Completed AMSURG Acquisition
Ascension, one of the nation’s leading Catholic and non-profit health systems, has officially completed its acquisition of AMSURG, bringing together two organizations committed to expanding access to compassionate, high-quality outpatient care across the country.
Mechanism of Pneumopericardium During Pericardiocentesis
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Cath Lab Digest or HMP Global, their employees, and affiliates. Shashwat Joshi, MBBS Junior Resident, Department of Cardiology, AIIMS, New Delhi, India Dr. Joshi can be contacted at shashwatjoshi000@gmail.com.
Client Challenge
JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.
Edwards’ Structural Heart Leadership Demonstrated Through Expanding Body of Scientific Evidence at New York Valves
NEW YORK--Edwards Lifesciences announced new data presented at New York Valves 2026, the annual conference organized by the Cardiovascular Research Foundation, which reinforce the company's leadership in advancing high-quality scientific evidence and innovating for patients. These new data – spanning aortic, mitral and tricuspid therapies – provide further understanding of the complexity of structural heart disease and the need for innovative treatment options.